

34 **Abstract**

35 The detection of SARS-CoV-2-specific antibodies in the serum of an individual indicates prior infection
36 or vaccination. However, it provides limited insight into the protective nature of this immune response.
37 Neutralizing antibodies recognizing the viral Spike are far more revealing, yet their measurement
38 traditionally requires virus- and cell-based systems that are costly, time-consuming, poorly flexible and
39 potentially biohazardous. Here we present a cell-free quantitative neutralization assay based on the
40 competitive inhibition of trimeric SARS-CoV-2 Spike protein binding to the angiotensin converting
41 enzyme 2 (ACE2) viral receptor. This high-throughput method matches the performance of the gold
42 standard live virus infectious assay, as verified with a panel of 206 seropositive donors with varying
43 degrees of infection severity and virus-specific IgG titers, achieving 96.7% sensitivity and 100%
44 specificity. Furthermore, it allows for the parallel assessment of neutralizing activities against multiple
45 SARS-CoV-2 Spike variants of concern (VOC), which is otherwise unpredictable even in individuals
46 displaying robust neutralizing antibody responses. Profiling serum samples from 59 hospitalized
47 COVID-19 patients, we found that although most had high activity against the 2019-nCoV Spike and to
48 a lesser extent the B.1.1.7 variant, only 58% could efficiently neutralize a Spike derivative containing
49 mutations present in the B.1.351 variant. In conclusion, we have developed an assay that has proven
50 its clinical relevance in the large-scale evaluation of effective neutralizing antibody responses to VOC
51 after natural infection and that can be applied to the characterization of vaccine-induced antibody
52 responses and of the potency of human monoclonal antibodies.

53

54 **Main**

55 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a global crisis
56 with a devastating impact on public health, societies and economies around the world.(1, 2) The
57 majority of individuals infected with SARS-CoV-2 experience mild to moderate symptoms that do not
58 require hospitalization but risk factors including age, ethnicity, gender, obesity and underlying health
59 issues including cardiovascular disease, diabetes and chronic respiratory disease can lead to severe
60 illness. (3) COVID-19, the disease caused by SARS-CoV-2 infection, has so far resulted in >2.5 million
61 deaths worldwide and it is estimated that approximately 5-10% of symptomatic infected individuals
62 will have longer term health consequences.(4)

63 The global spread of SARS-CoV-2 led to the rapid development of diagnostic tools including viral
64 detection tests and serological assays to assist in the public health management of the pandemic.(5,
65 6) Seroprevalence studies generally search for the presence of virus-specific antibodies in the serum
66 of individuals as a marker of previous infection or, albeit still too rarely, vaccination. However, these

67 analyses do not assess whether the detected immune response is protective.(7) Indeed, only a subset
68 of antibodies mounted against a virus can block its spread. These are called neutralizing antibodies,
69 and in the case of SARS-CoV-2 they recognize Spike (S), the viral surface protein responsible for
70 mediating entry through binding of the ACE2 viral receptor.(8) (9)

71 The gold standard for measuring levels of SARS-CoV-2-specific neutralizing antibodies relies on
72 infection of ACE2-expressing cells with live virus, monitoring the reduction in the culture of virus-
73 induced cytopathic effects (CPE) or, if a virus modified to encode GFP or luciferase is used, the
74 expression of these reporters. (10) Such neutralization assays are not routinely performed because
75 they are technically demanding, take several days for readout and require trained professionals
76 working in biosafety level 3 (BSL3) facilities. As an alternative, viral pseudotypes can be utilized,
77 typically lentiviral vector (LV) or vesicular stomatitis virus (VSV) particles coated with the SARS-CoV-2
78 S protein to drive their entry into ACE2-positive target cells. Although compatible with the less
79 constrained environment of biosafety level 2 laboratories, these assays still require cell culture and
80 take several days.(11) Furthermore, neither LV nor VSV pseudotypes fully recapitulate SARS-CoV-2
81 infectivity, because their virions assemble at the plasma membrane whereas the coronavirus loads its
82 S protein in the endoplasmic reticulum-Golgi intermediate compartment.(12) As a result, these S-
83 pseudotyped virions are difficult to produce as highly infectious particles and are inherently easier to
84 neutralize compared to the authentic SARS-CoV-2 virus, leading to often erratic estimations of the
85 neutralizing activity of biological samples.

86 Measuring the neutralizing activity of virus-specific antibodies is further complicated by the continuous
87 emergence of SARS-CoV-2 variants. Some of these variants are of particular clinical relevance, such as
88 ones with mutations in and around the receptor binding domain (RBD) of the S protein, resulting in
89 increased affinity for the ACE2 receptor or reduced recognition by neutralizing antibodies.(13, 14) For
90 instance, the B.1.351 (also called 501Y.V2 or South African variant of concern (VOC)) has been found
91 largely to escape immunity induced by some COVID-19 vaccines,(15) and the closely related P.1 (also
92 called 501Y.V3, B.1.1.28 or Brazilian VOC) to be responsible for large numbers of reinfections in the
93 Manaus region. (16)

94 To address these challenges, we developed a cell-free neutralization assay based on the competitive
95 inhibition of ACE2 binding to S protein trimers-bearing beads. This method is high-throughput,
96 quantitative, yields results tightly correlating those obtained with a classical wild-type virus cell-based
97 neutralization assay, and allows the simultaneous evaluation of multiple S protein variants. Illustrating
98 its value, it reveals that some previously infected individuals display variant-specific serum neutralizing
99 antibody titers, suggesting that they remain at risk of infection with at least some VOCs. Based on

100 these results, we propose that this novel assay stands to play an important role in analyzing the
101 protection induced by SARS-CoV-2 infection or vaccination, thus facilitating the determination and
102 certification of individuals' antiviral immunity status and the adaptation of vaccines to the potential
103 emergence of escape variants.

104

105 **Results**

106 A cell-free SARS-CoV-2 S protein trimer /ACE2-based neutralization assay

107 SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as its primary receptor, which it recognizes
108 via the receptor binding domain (RBD) of its S protein.(17) In return, this 211 amino acid-long region is
109 the main target of neutralizing antibodies.(8, 18, 19) We thus hypothesized that an assay capable of
110 providing a quantitative measurement of the inhibition of SARS-CoV-2 S protein interaction with ACE2
111 could reveal the neutralizing potential of antibodies found in serum and other biological samples.
112 However, whereas a previously described system based on this assumption relied on the sole use of S
113 protein RBD monomers,(20) we reasoned that having the full S protein in trimeric higher order
114 structure, as found on the surface of the virion, was more likely to recapitulate the physiological
115 configuration. (21) Therefore, we produced S protein trimers (S³) in native prefusion configuration (22)
116 in CHO cells and coupled these proteins to Luminex beads. We then measured the ability of these S³-
117 bearing beads to recruit a recombinant human ACE2 mouse Fc-tagged fusion protein (ACE2-Fc), which
118 we detected with a fluorescently tagged anti-mouse Fc secondary antibody. A standard protocol was
119 then established (**Figure 1a**), whereby after S³-carrying beads are first mixed in a 96-well plate with
120 limited dilutions of test serums, before adding ACE2-Fc and pursuing incubation for 60 min in order to
121 reach equilibrium, and finally measuring the amount of captured soluble viral receptor with a
122 fluorescently tagged antibody on a Bio-Plex 200 System. Using this procedure, we first verified that
123 serum samples from pre-COVID-19 pandemic healthy donors (n=104, **Figure 1b-c**) did not significantly
124 cross-react (2) and interfere with ACE2-Fc binding to S³-coupled beads, whereas serum from post-
125 infected donors induced a dilution-dependent signal reduction (**Figure 1d**).

126 We went on to validate the surrogate neutralization assay with a panel of 206 post-infection serums
127 obtained from individuals, some with a prior history of RT-PCR-documented symptomatic infection
128 requiring or not hospitalization (n=95), and others without known SARS-CoV-2 antecedent but
129 identified as seropositive in a Swiss population serological survey (n=111). As expected, an inverse
130 correlation was noted when comparing these two groups between average serum anti-S protein IgG
131 and/or IgA levels and severity of previous disease (**Figure 2a-b**). These 206 serums were tested in

132 parallel with the cell-free S³-ACE2 assay and a conventional live CPE assay in Vero cells. The results
133 revealed a high correlation of the neutralizing titers obtained with the two assays ($R^2 = 0.825$) over the
134 >3 log range measured amongst the various samples (**Figure 3a**). We additionally subjected a subset
135 of these serums (n=75) to a LV reporter pseudotype-based neutralization assay, which revealed a
136 weaker correlation with the live virus assay ($R^2 = 0.65$, n=75; **Figure 3b**).

137 For the S³-ACE2 neutralization assay, a lower limit IC₅₀ serum dilution of 50 was set as the specificity
138 cutoff using IC₅₀ values for the 104 pre-COVID-19 pandemic healthy donor samples (mean IC₅₀ of 12.5
139 + 4 × 9.0 SD; **Figure 1b**). A serum dilution IC₅₀ of 20 was selected as the cutoff for positivity in the live
140 SARS-CoV-2 virus CPE assay given that this corresponds to 95-99% viral neutralization (using Nonlinear
141 regression with 1 and 1.5 Hill slopes values to achieve IC₉₅ and IC₉₉, respectively; **Supplemental Figure**
142 **1**) for the undiluted serum sample.(23) Using these criteria, the surrogate neutralization assay was
143 determined to achieve 96.7% sensitivity (118 out of 122) and 100% specificity (0 out of 84) relative to
144 the live virus CPE assay (**Table 1**). Additionally, samples with moderate blocking activity in the S³-ACE2
145 neutralization assay (serum dilution 1:50 to 1:100) strongly correlated with samples that exhibited
146 weak (1:20 to 1:50) to moderate (1:50 to 1:100) neutralizing activities in the live virus assay.

147

148 Multiplexed measurement of SARS-CoV-2 VOCs neutralization

149 A characteristic of Luminex bead-based assays is the use of analytical optics that allow for the
150 simultaneous evaluation of analytes captured by multiple baits, each coupled to beads of different
151 colors. We took advantage of this feature to test in parallel the neutralization potential of post-
152 infection serums against a large array of SARS-CoV-2 S protein variants. For this, we produced a set of
153 S protein derivatives containing specific mutations alone or in combination, amongst which amino acid
154 changes suspected to contribute to immune escape of some VOCs, such as substitutions at positions
155 K417, E484 and N501 found in the B.1.1.7 (501Y.V1 or UK variant), B.1.351 (501Y.V2 or South African
156 variant) and P.1 strains (501Y.V3 or Brazilian variant) (**Table 2**)(15, 16, 24). We then coupled each of
157 the corresponding S protein trimers to beads of a given color, and placed equal amounts of each of
158 these beads in the wells of a 96-well plate. To validate the utility of the S³-ACE2 assay in identifying S
159 protein mutations conferring reduced sensitivity to neutralization, concentration response curves
160 were generated with the REGN10933 therapeutic antibody profiled against the K417N/E484K/N501Y
161 and Δ69-70 Y453F S protein mutations present in the B.1.351 and mink SARS-CoV-2 variants,
162 respectively (**Figure 4a**). Consistent with published results, REGN10933 had a significant loss in potency
163 against S proteins harboring mutations from either the B.1.351 (61-fold loss in IC₈₀ activity) or mink
164 variants (67-fold loss in IC₈₀ activity) (16, 25). We then performed the neutralization assay on a large

165 series of post-infection serums, selected examples of which are illustrated in **Figure 4b-c**. In an S
166 protein panel consisting of single amino acid mutations, two donors both exhibited high neutralizing
167 antibody titers ($>1,000$ IC₅₀) against the original 2019-CoV S protein, as measured in duplicates with
168 beads of two different colors. However, while one (sample 3506) retained full potency against a series
169 of seven S protein point mutants, the other (sample 9504) displayed a >2 log reduced ability to block
170 the interaction of ACE2 with the E484K S protein mutant, a result corroborated in the LV pseudotype
171 reporter assay (**Supplemental Figure 2**).

172 An additional panel of S³-coupled beads was manufactured to evaluate mutations present in the 501Y
173 lineage circulating SARS-CoV-2 variants, including the so-called B.1.1.7 and B.1.351 or P.1 VOCs (**Figure**
174 **2b-c**). A representative donor (sample 1034) exhibited neutralizing antibody levels in the higher range
175 of activity (>100 IC₅₀ serum dilution) against the 2019-nCov S protein but only retained moderate
176 blocking activity (50 to 100 IC₅₀; yellow range in **Figure 2c**) against most of the singly or multiply
177 mutated S protein derivatives. Importantly, this serum was almost completely inefficient against S
178 proteins containing the E484K mutation found in the B.1.351 and P.1 VOCs (<50 IC₅₀; light red range).
179 Another serum (sample 5537) had a stronger overall neutralization activity but still displayed lower
180 efficacy against S protein derivatives harboring the E484K mutation or against the B.1.1.7 variant (IC₅₀
181 serum dilutions between 30 and 76).

182 To illustrate the high-throughput screening capability of the S³-ACE2 assay, neutralizing antibody titers
183 against the 2019-CoV and three S protein variants were evaluated in serum from 59 COVID-19 patients
184 hospitalized with (n=31) or without (n=28) need for intensive care unit (ICU) stay (**Figure 3**). The
185 majority of patients from both subgroups, all of whom had been infected prior to November 2020,
186 exhibited strong neutralizing activity when profiled against the 2019-nCoV S protein, with 93% of non-
187 ICU and 100% of ICU patients having greater than 50 serum dilution IC₅₀ cut-off. Based on our cross-
188 validation studies, this cut-off value corresponds to antibody levels in undiluted serum samples that
189 would be sufficient to achieve near complete neutralization in the live virus CPE assay (**Supplementary**
190 **Figure 1**) However, they were less efficient at blocking ACE2 interaction with the S protein found in
191 the B.1.1.7 variant or derivatives containing the S477N substitution or the K417N/E484K/N501Y triple
192 RBD mutation encountered in the B.1.351 variant. Both groups notably exhibited a marked reduction
193 in median IC₅₀ against this latter allele ($P<0.0001$), with only 58% (43% of non-ICU and 71% of ICU
194 patients) displaying antibody levels above the 50 serum IC₅₀ cut-off. ICU patients additionally
195 presented a weak but significant median increase in neutralizing antibody levels for each of the S
196 proteins tested compared to non-ICU patients ($P=0.0127$ to 0.0425), consistent with a model whereby
197 more severe and prolonged infections lead to stronger humoral immune responses.

198 Discussion

199 Determining the level of immune protection conferred by prior SARS-CoV-2 infection, vaccination or
200 the prophylactic administration of monoclonal antibodies is of paramount importance for informing
201 individuals about their susceptibility to the virus, for adapting prophylactic measures to the evolving
202 viral strains circulating in the population and, ultimately, for controlling the COVID-19 pandemic. While
203 T-cell-based responses may contribute to this immunity,(26) neutralizing antibodies likely play a
204 primary role in this process as they do for other acute viral infections, and represent the best available
205 surrogate marker of protection. (9, 27) However, serum levels of SARS-CoV-2 neutralizing antibodies
206 are so far only rarely measured owing to overwhelming technical difficulties and biosafety
207 requirements, which preclude any sort of routine procedure or significant scale-up.

208 Addressing this shortcoming, we report here the development of a cell-free assay that allows for the
209 quantitative and high-throughput evaluation of the neutralizing activity of biological samples such as
210 serum against multiple SARS-CoV-2 variants in a single procedure taking less than three hours in a
211 standard diagnostic laboratory. The S³-ACE2 assay relies on the fact that most neutralizing antibodies
212 interfere with the binding of the viral S protein with its ACE2 receptor. Although neutralizing antibodies
213 have been identified that recognize S protein outside of the RBD (9) and do not directly impact on ACE2
214 binding, these are rare and likely contribute minimally to antiviral immunity, as confirmed by the very
215 high degree of correlation between our surrogate assay and its live virus cell-based reference
216 counterpart, irrespective of the levels of neutralizing activity.(8) Our assay provides quantitative
217 measures of serum neutralizing antibody levels and is further characterized by a very high degree of
218 sensitivity and specificity (>96% and 100%, respectively, using the herein described protocol).

219 A significant advantage of the S³-ACE2 neutralization assay is its ability to evaluate multiple S variants
220 in parallel using as little as 15 μ l of serum, allowing the identification of an individual's susceptibility to
221 circulating and emerging SARS-CoV-2 viruses, whether after infection or vaccination. This was
222 demonstrated with serum samples from 59 COVID-19 patients infected prior to the widespread
223 emergence of VOCs. Importantly, only 43% of non-ICU hospitalized patients had neutralizing antibody
224 levels greater than 50 serum dilution IC₅₀ against the S protein with the K417N/E484K/N501Y mutation
225 found in the B.1.351 variant, suggesting that many are not protected against this strain. The P.1 variant
226 originally identified in Brazil has a similar mutation profile in the RBD and some of these non-ICU
227 patients would be anticipated to be equally susceptible to infection by this SARS-CoV-2 variant as well.
228 Individuals whose infection had required an ICU stay generally displayed higher levels of neutralizing
229 antibodies against all tested S protein variants, although they too were less effective against the
230 B1.351/P1 triple mutant.


231 The multiplexing of the S³-ACE2 neutralization assay could be increased to >40 different S alleles to
232 tackle new VOCs. It advantageously compares with viral pseudotypes-based systems, where each S
233 protein mutant requires production of a new batch of virions that have to be tested in separate assays,
234 with their infectivity potentially affected by the mutations and neutralization titers influenced by the
235 levels of ACE2 on the surface of target cells (28, 29). As levels of anti-SARS-CoV-2 immunity increase
236 in the world population due to the combined influence of ongoing infections and more widespread
237 vaccination, selective pressures will increasingly be exerted on the virus favoring the emergence of
238 escape mutants. The detection of these escapees should be as fast as possible for the swift adaptation
239 of prophylactic measures including vaccines. While the infection of previously infected or vaccinated
240 individuals will remain the strongest evidence of gaps in the collective immunity, a surveillance system
241 based on the routine sequencing of viral isolates and the immediate testing of the susceptibility of
242 their S protein to neutralization would constitute a far more dynamic and anticipatory approach. The
243 S³-ACE2 assay, because of its ease of use, would facilitate such surveillance strategy. Furthermore, it
244 could also be used for the high-throughput screening of candidate monoclonal antibodies and other
245 prophylactic or therapeutic approaches aimed at blocking the interaction between SARS-CoV-2 and its
246 cellular receptor, and it could be adapted to other viruses for which the molecular mediators of viral
247 entry are properly characterized.

248 Therefore, the hereby described method stands to have an important impact in both clinical and public
249 health settings. In this regard, immunity passports are at the forefront of current public and political
250 discussions as possible gateways to a return to more normal social and international exchanges, as the
251 world emerges from the COVID-19 pandemics (30). They are generally thought of essentially as
252 vaccination certificates, a concept that suffers from major shortcomings. First, such certificates would
253 unduly exclude people that have not yet been vaccinated but endowed with strong antiviral immunity
254 triggered by natural infection. Second, they would not be delivered to individuals that do not respond
255 to vaccination such as primary or acquired immunodeficiency patients and/or cancer, transplant and
256 patients with systemic inflammatory diseases receiving immunosuppressive treatments. These
257 individuals could however be protected by passive immunization through the administration of human
258 monoclonal antibodies, the activity of which could be quantified in their serum (31-33). Third, having
259 been vaccinated is not a guarantee of induction of optimal immunity and protection, as found every
260 year with the flu vaccine, and the duration of vaccine-induced SARS-CoV-2 immunity is as yet unknown.


261

262

263



264



265

266 **Figure 1: Outline and validation of a cell-free SARS-CoV-2 S protein trimer /ACE2 surrogate**

267 **neutralization assay.** (a) Schematic outline of the S^3 /ACE2 neutralization assay. Anti-SARS-CoV-2

268 serum antibodies are monitored for their capacity in blocking the S^3 /ACE2 interaction. ACE2 binding to S protein was detected through use of a fluorescently labeled secondary antibody and the signal

269 intensities are inversely proportional to the neutralizing potential of the anti-S protein antibodies. (b)

270 Serum dilution IC_{50} values were calculated for 104 healthy adult donor samples collected prior to

271 November 2019 (pre-COVID-19 pandemic). The mean IC_{50} values and SD were used to establish a

272 lower limit cutoff of 50 indicated by the dashed line (mean IC_{50} of $12.5 + 4 \times 9.0$ SD = 50 serum

273 dilution). (c) Representative concentration response curves for ten healthy donor serum samples

274 and (d) ten SARS-CoV-2 seropositive donors with varying levels of anti-S protein IgG antibody. Mean

275 \pm s.d. shown in graph b. S protein / ACE2 structure was generated with PDB 7a98.

276

277


278

279

280

281

282



283

284 **Figure 2: Anti-S protein IgG and IgA levels in the seropositive donor groups.** Anti-S protein IgG (a)
285 and IgA (b) antibody levels measured in the serum samples of different donor groups using a Luminex
286 Spike trimer serological assay. Donors were seropositive for anti-S protein IgG and/or IgA antibodies
287 with positivity cutoffs of 4 and 6.5 ratios over a standard negative control, respectively (red dashed
288 line in (a) and (b)(21). Donor groups consist of seropositive volunteers, randomly selected individuals
289 from the general population and donors that were in contact with a RT-PCR confirmed infected
290 subject (n=111) with reduced level of symptoms and symptomatic RT-PCR positive donors that were
291 either hospitalized COVID-19 patients or not (n=95). Boxplots shown mean and the 95% interquartile
292 range.

293

294

295

296

297

298

299

300

301


302

303

304

305


306



307

308 **Figure 3: Cross-validation of a cell-free SARS-CoV-2 S protein trimer /ACE2 surrogate neutralization**
309 **assay. (a)** Cross-validation studies between S³/ACE2 surrogate neutralization assay and the “gold
310 standard” SARS-CoV-2 cytopathic effect (CPE) neutralization assay. Seropositive donors (n=206) with
311 varying levels of anti-S protein antibodies were selected for comparison of the assays. Donors
312 consisted of COVID-19 hospitalized patients (n=31), symptomatic infected donors with RT-PCR-
313 documentation (n=64) and other seropositive donors identified through random sampling, volunteers
314 or contact with a confirmed SARS-CoV-2 infected individual in a Swiss population serological survey
315 (n=111). **(b)** Correlation between the live SARS-CoV-2 virus cytopathic effect and S protein
316 pseudotyped neutralization assays. A group of 74 samples from S protein seropositive donors were
317 compared in the live virus CPE and S protein pseudotyped virus cell based neutralization assays.
318 Correlation between the two neutralization assays is represented by the black dashed line and the 20
319 serum dilution IC₅₀ cutoff for positivity in the CPE assay is shown with the blue dashed line.

320



321


322 **Figure 4: Multiplexed analysis of antibody and serum neutralizing activity against VOC S protein**
 323 **mutations.** The surrogate neutralization assay was performed with two panels of S³ coupled beads
 324 consisting of the 2019-nCov S protein and S mutations produced with one or more amino acid
 325 substitutions or deletions. (a) Concentration response curves of the REGN10933 therapeutic
 326 antibody evaluated against S protein mutations from three viral variants in the S³/ACE2 assay. (b-c)
 327 Serum dilutions from RT-PCR positive donors 3506 and 9504 (b) or 1034 and 5537 (c) in the S³-ACE2
 328 assay with two separate panels of S³ coupled beads. (c) Spider plot and heatmap showing IC₅₀ serum
 329 dilutions for donors 1034 and 5537 serums samples against the indicated S protein mutations found
 330 in variants of concern including B.1.1.7 and P1. In these graphs, green background corresponds to an

331 IC_{50} dilution >100 for strong blocking of the $S^3/ACE2$ interaction, yellow background for moderate
 332 blocking with IC_{50} dilutions from 50 to 100 and red background for low to no blocking activity against
 333 the indicated S protein mutant.

334

335

336



337

338 **Figure 5: Multiplexed analysis of COVID-19 patient serum samples for neutralizing activity against**
 339 **variant of concern S protein mutations.** Serum samples from 59 COVID-19 hospitalized patients were
 340 profiled in the multiplexed $S^3/ACE2$ surrogate neutralization assay performed in parallel with the 2019-
 341 nCov S protein and three S mutants produced with one or more amino acid substitutions or
 342 deletions. $S^3/ACE2$ serum dilution IC_{50} values for each of the S proteins were calculated for samples
 343 from the 28 COVID-19 hospitalized donors that remained on the wards (non-ICU, closed symbols) and
 344 for 31 COVID-19 patients that were critically ill, requiring treatment by the intensive care unit (ICU,
 345 open symbols). Dashed red line indicates the 50 serum dilution IC_{50} value cut-off in the $S^3/ACE2$ assay
 346 that corresponds to neutralizing antibody levels needed for near complete (>99%) neutralization in the
 347 live virus CPE assay. Percentages of serum samples above this cut-off are shown for non-ICU and ICU
 348 donors for each of the S proteins tested. Median values are shown as a red bar for each of the data
 349 sets. Statistical analysis was performed using the non-parametric Mann-Whitney t-test and showed
 350 that ICU patients had higher levels of neutralizing antibodies compared to non-ICU patients ($P=0.0127$
 351 to 0.0425) when compared for the same S protein. In comparisons between S proteins, reduced levels
 352 of neutralizing antibodies against the S protein with K417N/E484K/N501Y mutations were strongly
 353 significant ($P<0.0001$) relative to the 2019-nCoV S protein.

354

355

356 **Table 1: Benchmarked performance of the cell-free S³ /ACE2 surrogate neutralization assay against**
 357 **the SARS-CoV-2 live virus CPE neutralization assay**

358

		Neutralizing activity in the live virus CPE assay (IC ₅₀ serum dilution)	
		Below lower limit cutoff for neutralizing activity (<20 IC ₅₀ ; n= 84)	Positive neutralizing activity (>20 IC ₅₀ ; n= 122)
S ³ / ACE2 assay (IC ₅₀ serum dilution)	Below lower limit ACE2 blocking cutoff (< 50 IC ₅₀ ; n=88)	n=84 S ³ / n=84 CPE	3.2% False negative n=88 S ³ / n=4 CPE
	Positive for ACE2 blocking activity (>50 IC ₅₀ ; n=118)	0% False positive n=0 S ³ / n=84 CPE	96.7% Sensitivity n=118 S ³ / n=122 CPE

359

360

361

362 **Table 2: S protein mutations in different circulating SARS-CoV-2 variants of concern**

363

SARS-CoV-2 Variant	S protein mutations
B.1.1.7 / 501Y.V1	Δ69-70, Δ144, N501Y, A570D, D615G, P681H, T716I, S982A, D1118H
B.1.351 / 501Y.V1	L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V
P.1 / 501Y.V3	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F

364

365

366

367

368

369

370

371

372

373


374

375

376

377

378




379

380

381

382 **Supplemental Figure 1: Selection of a positive cutoff values in the live virus CPE neutralization**
 383 **assay.** Simulated data generated to illustrate that maximum viral inhibitions of 95% and 99% would
 384 be obtained with a serum dilution IC₅₀ of 20 using either Hill slope values of 1.0 and 1.5, respectively.

385



386

387

388 **Supplemental Figure 2: Neutralization activity of donor sera tested against pseudotyped viruses**
 389 **produced with different S protein mutations.** Concentration response curves generated for donor
 390 3506 (a) and 9504 (b) serum samples in the SARS-CoV-2 S protein pseudoviral assay using either the
 391 2019-nCov D614G, S477N/ D614G or E484K D614G S protein pseudotyped particles. Graphs show the
 392 mean of $n=2 \pm$ s.d.

393

394

395

396 **Supplemental Table 1: Primers used to construct Spike mutants**

nCov S mutants cloning	Primers
O.PTSP.His.1(f)	GGCCGAGTTCGGTAC
O.PTSP.His.2(b)	GATGATGCTCTGGCTAG
O.PTSP.His.4(b)	GTATTGCAGCAGCAGGTTGCTG
O.del69-70 (F)	GTTCCACGCCATCAGCGGCACAAACG
O.del69-70 (R)	CGTTTGTGCCGCTGATGGCGTGGAAC
O.M153T (F)	CAAGAGCTGGACGAAAGCGAG
O.M153T (R)	CTCGCTTCCGTCCAGCTCTTG
O.K417N (F)	CCAGACCGGTAACATCGCTGACTAC
O.K417N (R)	GTAGTCAGCGATGTTACCGGTCTGG
O.N439K (F)	CCTGGAAGCTCTAAGAAGCTGGATAG
O.N439K (R)	CTATCCAGGTTCTTAGAGTTCCAGG
O.Y453F (F)	CAACTACCTGTTCCGGCTGTTTC
O.Y453F (R)	GAAACAGCCGGAACAGGTAGTTG
O.S459Y (F)	GTTTCGCAAGTATAACCTGAAAC
O.S459Y (R)	GTTTCAGGTTATACTTGCAGAAAC
O.S477N (F)	CCAGGCCGGAATACACCTTGTAAC
O.S477N (R)	GTTACAAGGTGTATTACCGGCCTGG
O.S477R (F)	CCAGGCCGGTCTGACACCTTGTAAC
O.S477R (R)	GTTACAAGGTGTACGACCGGCCTGG
O.E484K (F)	GTAACGGGGTGAAGGGCTTCAACTG
O.E484K (R)	CAGTTGAAGCCCTTACCCCGTTAC
O.N501T (F)	CTTCCAGCTACCACTGGAGTCGGCTACC
O.N501T (R)	GGTAGCCGACTCCAGTGGTAGGCTGGAAG
O.N501Y (F)	CTTCCAGCTACCTATGGAGTCGGCTAC
O.N501Y (R)	GTAGCCGACTCCATAGGTAGGCTGGAAG
O.D614G.1(f)	GTGCTGTACCAAGGTGTTAACTGCAC
O.D614G.2(b)	GTGCAGTTAACACCTTGGTACAGCAC
O.P681H (F)	CAGACAAACAGCCATGGGTCTGCTTCC
O.P681H (R)	GGAAGCAGACCCATGGCTGTTTGTCTG

HDM-IDT-S-Fix mutants cloning	Primers
O.IDM.1(f)	CTGGCCCATCACTTTGGCAAAG
O.IDM.2(b)	GGCAGAATCTCAGTGGTGACCGAAATAGTG
O.Wu-1_D614G.(f)	GGG ACC AAC ACC TCC AAC CAA GTC GCG GTC CTC TAT CAA GGG GTC AAC TGT ACG GAA GTA
O.Wu-1_D614G.(b)	CCG GTA CTT CCG TAC AGT TGA CCC CTT GAT AGA GGA CCG CGA CTT GGT TGG AGG TGT TGG TCC C
O.S477N.1(f)	CAAGCCGGCAATACACCATG
O.S477N.2(b)	CATGGTGTATTGCCGGCTTG
O.E484K.1(f)	GTAATGGTGTGAAGGGCTTTAAC
O.E484K.2(b)	GTAAAGCCCTTACACCATTAC

398 **Material and Methods**

399

400 **Study populations**

401 **Seropositive donors**

402 Cross-validation studies were performed on serum samples identified from the
403 seroprevalence study of the Vaud Canton in Switzerland (SerocoViD) performed by the Centre
404 for Primary Care and Public Health, University of Lausanne (Unisanté), from the Swiss
405 Population based seroprevalence study performed by Coronas Immunitas and from the with
406 hospitalized donor ImmunoCov study performed by the Immunology and Allergy Service,
407 Lausanne University Hospital. The panel of 206 SARS-CoV-2 seropositive samples consists of:
408 31 hospitalized COVID-19 patients and 64 RT-PCR positive non-hospitalized donors for a total
409 of 95 RT-PCR donors and 111 seropositive donors identified through contact with RT-PCR
410 positive donors, volunteers and asymptomatic or pausisymptomatic donors selected at
411 random from the general population. Serum samples from 59 COVID-19 patients hospitalized
412 with (n=31) or without (n=28) need for stay in the intensive care unit were selected from
413 donors participating in the ImmunoCov study and Unisanté studies.

414

415 **Pre-COVID-19 pandemic donors**

416 Negative control serum samples from 90 adult healthy donors with ages ranging for 18 to 81
417 years of age were collected prior to November 2019 as part of the Swiss Immune Setpoint
418 study sponsored by Swiss Vaccine Research Institute. Study design and use of subject sera
419 samples were approved by the Institutional Review Board of the Lausanne University Hospital
420 and the 'Commission d'éthique du Canton de Vaud' (CER-VD) stated that authorization was
421 not required.

422

423 **Production of SARS-CoV-2 S proteins**

424 The S protein trimer was designed to mimic the native trimeric conformation of the protein in
425 vivo and the expression vector was kindly provided by Prof. Jason McLellan, University of
426 Texas, Austin. It encoded the prefusion ectodomain of the original 2019-Cov S protein with a
427 C-terminal T4 foldon fusion domain to stabilize the trimer complex along with C-terminal 8x
428 His and 2x Strep tags for affinity purification. The trimeric Spike protein was transiently
429 expressed in suspension-adapted ExpiCHO cells (Thermo Fisher) in ProCHO5 medium (Lonza)
430 at 5 x10⁶ cells/mL using PEI MAX (Polysciences) for DNA delivery. At 1 h post-transfection,
431 dimethyl sulfoxide (DMSO; AppliChem) was added to 2% (v/v). Following a 7-day incubation
432 with agitation at 31 °C and 4.5% CO₂, the cell culture medium was harvested and clarified
433 using a 0.22 µm filter. The conditioned medium was loaded onto Streptactin (IBA) and
434 StrepTrap HP (Cytiva) columns in tandem, washed with PBS, and eluted with 10 mM
435 desthiobiotin in PBS. The purity of S protein trimers was determined to be > 99% pure by SDS-
436 PAGE analysis. Generation of S protein expression vectors encoding the mutations D614G,

437 D614G plus M153T, N439K, S477N, S477R, E484K, S459Y, N501T, N501Y, K417N, Δ 60-70,
438 P681H, Y453F or combinations thereof were generated by InFusion-mediated site directed
439 mutagenesis using primers listed in Supplementary Table 1. The B1.1.7 variant clone was
440 generated by gene synthesis (Twist Biosciences). S proteins for all mutants were produced
441 and purified in an identical manner to the original 2019-Cov S protein.

442

443 **Coupling of Luminex beads with SARS-CoV-2 S protein**

444 Luminex beads used for the serological binding assays were prepared by covalent coupling of
445 SARS-CoV-2 proteins with MagPlex beads using the manufacture's protocol with a Bio-Plex
446 Amine Coupling Kit (Bio-Rad, France). Briefly, 1 ml of MagPlex-C Microspheres (Luminex) were
447 washed with wash buffer and then resuspended in activation buffer containing a freshly
448 prepared solution of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-
449 hydroxysulfosuccinimide (S-NHS), (ThermoFischer, USA). Activated beads were washed in PBS
450 followed by the addition of 50 μ g of protein antigen. The coupling reaction was performed at
451 4 °C overnight with bead agitation using a Hula-Mixer (ThermoFischer). Beads were then
452 washed with PBS, resuspended in blocking buffer then incubated for 30 minutes with agitation
453 at room temperature. Following a final PBS washing step, beads were resuspended in 1.5 ml
454 of storage buffer and kept protected from light in an opaque tube at 4 °C. Each of the SARS-
455 CoV-2 proteins was coupled with different colored MagPlex beads so that tests could be
456 performed with a single protein bead per well or in a multiplexed Luminex serological binding
457 assay.

458

459 **Cell-free S protein /ACE2 surrogate neutralization assay**

460 S protein coupled beads are diluted 1/100 in PBS with 50 μ l added to each well of a Bio-Plex
461 Pro 96-well Flat Bottom Plates (Bio-Rad). Following bead washing with PBS on a magnetic plate
462 washer (MAG2x program), 80 μ l of individual serum samples at different dilutions (e.g. 1/10,
463 1/30, 1/90, 1/300, 1/2700 and 1/8100) in PBS were added to the plate wells. Control wells
464 were included on each 96-well plate that included beads alone, matching serum dilutions of a
465 control pool of pre-COVID-19 pandemic healthy human sera (BioWest human serum AB males;
466 VWR) and a positive control commercial anti-Spike blocking antibody (SAD-S35 from ACRO
467 Biosciences) or recombinant produced REGN10933 neutralizing antibody discovered and
468 marketed by Regeneron tested in a concentration response. Plates were agitated on a plate
469 shaker for 60 minutes then the ACE2 mouse Fc fusion protein (Creative Biomart or produced
470 by EPFL Protein Production and Structure Core Facility) was then added to each well at a final
471 concentration of 1 μ g/ml and agitated for a further 60 minutes. Beads were then washed on
472 the magnetic plate washer and anti-mouse IgG-PE secondary antibody (OneLambda
473 ThermoFisher) was added at a 1/100 dilution with 50 μ l per well. Plates were agitated for 45
474 minutes, washed, the beads resuspended in 80 μ l of reading buffer then read directly on a Bio-
475 Plex 200 plate reader (Bio-Rad). REGN10933 used in this study was a generous gift from
476 Berend-Jan Bosch, Utrecht University, Netherlands. MFI for each of the beads alone wells
477 were averaged and used as the 100% binding signal for the ACE2 receptor to the bead coupled

478 Spike trimer. MFI from the well containing the high concentration (> 1 µg/ml) of commercial
479 anti-Spike blocking antibody was used as the maximum inhibition signal. The percent blocking
480 of the S protein trimer / ACE2 interaction was calculated using the formula: % Inhibition = (1-
481 ([MFI Test dilution – MFI Max inhibition] / [MFI Max binding – MFI Max inhibition]) × 100).
482 Serum dilution response inhibition curves were generated with GraphPad Prism 8.3.0 using
483 NonLinear four parameter curve fitting analysis of the log(agonist) vs. response. Sensitivity,
484 specificity and correlative of the tests were calculated with Excel and GraphPad prism.

485

486 **SARS-CoV-2 live virus cell based cytopathic effect neutralization assay**

487 All the biosafety level 3 procedures were approved by the competent Swiss authorities. The
488 day before infection VeroE6 cells were seeded in 96-well plates at a density of 1.25x10E+4
489 cells per well. Heat inactivated sera from patients were diluted 1:10 in DMEM 2% FCS in a
490 separate 96-well plate. Four-fold dilutions were then prepared in DMEM 2% FCS in a final
491 volume of 60 µl. SARS-CoV-2 (hCoV-19/Switzerland/GE9586) viral stock (2.4x10E6/ml as
492 titrated on VeroE6 cells) diluted 1:100 in DMEM 2% FCS was added to the diluted sera at a 1:1
493 volume/volume ratio. The virus-serum mixture was incubated at 37°C for 1 hour then 100 µl
494 of the mixture was subsequently added to the VeroE6 cells in duplicates. After 48 hours of
495 incubation at 37°C cells were washed once with PBS and fixed with 4% formaldehyde solution
496 for 30 minutes at room temperature. Cells were washed once with PBS and plates were put
497 at 70°C for 15 minutes for a second inactivation. Staining was performed outside the BSL3
498 laboratory with 50 µl of 0.1% crystal violet solution for 20 minutes at RT. Wells were washed
499 3 times with water and plates were dried, scanned and analyzed for the density of live violet
500 stained cells using ImageJ software. For each 96-well plate, at least 4 wells were treated with
501 a negative pool of sera from pre-pandemic healthy donors and 4 wells with virus only and used
502 as negative and positive controls respectively. The percent inhibition of cytopathic effect of
503 the virus was calculated using the formula: % Inhibition = (1- ([cell density Test dilution – cell
504 density Max inhibition] / [cell density Max binding – cell density Max inhibition]) × 100. Serum
505 dilution response inhibition curves were generated with GraphPad Prism 8.3.0 using
506 NonLinear four parameter curve fitting analysis of the log(agonist) vs. response. Sensitivity,
507 specificity and correlative of the tests were calculated with Excel and GraphPad prism.
508 Neutralization IC₅₀ values were calculated as described above for the cell free neutralization
509 assay using the GraphPad prism NonLinear four parameter curve fitting analysis.

510

511 **Spike-pseudotyped lentivectors production and neutralization assays**

512 HDM-IDTSpike-fixK plasmid (a kind gift from J. Bloom) encoding for the Wuhan-Hu-1 SARS-
513 Cov2 Spike was modified using QuickChange mutagenesis to generate the D614G mutant and
514 D614G/S477N or D614G/E484K double mutants (primers used are listed in Table 1).Spike-
515 pseudotyped lentivectors were generated by co-transfecting HDM-IDTSpike-fixK, pHAGE2-
516 CMV-Luc-ZSgreen, Hgpm2, REV1b and Tat1b (a kind gift from J.D. Bloom) plasmids into 293T
517 cells for 24 hours with the following ratio 3/9/2/2/2 (18µg/ 56.7cm² plate) using Fugene
518 transfection reagent (Promega). The following day, cells were transferred in EpiSerf medium,

519 and cell supernatants were collected after 8 hours and 16 hours. Harvested supernatants were
520 pooled, clarified by low-speed centrifugation, filtered to remove cell debris and aliquoted.
521 Lentivector stocks were titrated and normalized for HIV antigen p24 content by ELISA
522 (Zeptomatrix).

523 In the pseudoviral neutralization assay, 293T cells stably expressing the ACE2 receptor were
524 suspended in DMEM medium with 10% FCS and seeded at 1.0×10^4 cells per well into 96-
525 well plates. After 5 hours in cell culture at 37 °C, three-fold dilutions of serum samples were
526 prepared and pre-incubated with the same amount of each pseudovirus in a final volume of
527 100 μ l in DMEM + 10% FCS. Following a further 1 hour incubation at 37 °C, the
528 pseudoviruses/serum mixture was added to the 293T ACE2 cells. After 48 hours of incubation
529 at 37 °C, a luciferase assay was performed to monitor pseudoviral infection, using the ONE-
530 Step™ Luciferase assay system as recommended by the manufacturer (BPS Bioscience). Viral
531 neutralization resulted in the reduction of the relative light units detected. Neutralization
532 IC50 values were calculated as described above for the cell free neutralization and CPE assays
533 using the GraphPad prism NonLinear four parameters curve fitting analysis.

534

535 **Acknowledgements**

536 We thank the Service of Immunology and Allergy at the Lausanne University Hospital for their
537 contributions in analysis of subject serum samples for levels of anti-S protein IgG and IgA
538 antibodies, Laurence Durrer and Soraya Quinche from PTPSP-EPFL for mammalian cell culture,
539 Michaël François and Kelvin Lau from PTPSP-EPFL for helping in purification of the S protein
540 trimer proteins and ACE2-Fc protein. We would like to thank the Trono laboratory, Caroline
541 Tapparel for the help to start the SARS-Cov2 related work and I. Eckerle for providing a SARS-
542 Cov2 isolate. We also thank Valerie D'Acromont from Centre for Primary Care and Public
543 Health, University of Lausanne, in Lausanne, Switzerland and Milo Puhan and Jan Fehr from
544 the University Hospital of Zurich for providing serum samples from the Unisanté and Swiss
545 Population based seroprevalence study performed by Coronas Immunitas, respectively.
546 Funding for this project was provided through the Lausanne University Hospital, through the
547 Swiss Vaccine Research Institute and through the Coronavirus Accelerated R&D in Europe
548 (CARE) IMI project to G.P., and through the EPFL COVID fund to D.T.

549

550 **Author contributions**

551 P.T. established and performed the live SARS-CoV-2 virus cytopathic effect neutralization
552 assay, designed the S protein mutations and cloning, analyzed the results and contributed to
553 the editing of the manuscript. C.F. conceived of and designed the S protein /ACE2 surrogate
554 neutralization assays, organized the testing of sera, analyzed the data, wrote the initial draft
555 and contributed to the editing of the manuscript. C.P. optimized the conditions for the S
556 protein /ACE2 surrogate neutralization assays, solidified the testing protocol into a robust
557 diagnostics assay and tested all the serum samples with this assay. A.F. prepared all batches
558 protein coupled Luminex beads. J.C. performed all pseudoviral assays; C.R. performed site

559 directed mutagenesis of the S protein constructs; F.P. and the Protein Production and Structure
560 Core Facility at the EPFL produced and purified the trimer S proteins. V.C. provided initial
561 stocks of titrated SARS-CoV-2 virus. D.T. and G.P. conceived the study design for testing of sera
562 from the different subject groups, analyzed the results and wrote the manuscript.

563

564

565 References

- 566 1. E. M. Abrams, S. J. Szeffler, COVID-19 and the impact of social determinants of health. *Lancet*
567 *Respir Med* **8**, 659-661 (2020).
- 568 2. P. Zhou *et al.*, A pneumonia outbreak associated with a new coronavirus of probable bat
569 origin. *Nature* **579**, 270-273 (2020).
- 570 3. F. Zhou *et al.*, Clinical course and risk factors for mortality of adult inpatients with COVID-19
571 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062 (2020).
- 572 4. C. H. Sudre *et al.*, Attributes and predictors of long COVID. *Nat Med*, (2021).
- 573 5. A. Petherick, Developing antibody tests for SARS-CoV-2. *Lancet* **395**, 1101-1102 (2020).
- 574 6. C. H. GeurtsvanKessel *et al.*, An evaluation of COVID-19 serological assays informs future
575 diagnostics and exposure assessment. *Nat Commun* **11**, 3436 (2020).
- 576 7. N. M. A. Okba *et al.*, Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody
577 Responses in Coronavirus Disease Patients. *Emerg Infect Dis* **26**, 1478-1488 (2020).
- 578 8. L. Piccoli *et al.*, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike
579 Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* **183**, 1024-1042
580 e1021 (2020).
- 581 9. C. O. Barnes *et al.*, Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal
582 Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842 e816 (2020).
- 583 10. J. B. Case *et al.*, Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects
584 against SARS-CoV-2-Mediated Pathogenesis in Mice. *Cell Host Microbe* **28**, 465-474 e464
585 (2020).
- 586 11. J. Nie *et al.*, Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-
587 2. *Emerg Microbes Infect* **9**, 680-686 (2020).
- 588 12. S. Klein *et al.*, SARS-CoV-2 structure and replication characterized by in situ cryo-electron
589 tomography. *Nat Commun* **11**, 5885 (2020).
- 590 13. S. Ozono *et al.*, SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced
591 ACE2-binding affinity. *Nat Commun* **12**, 848 (2021).
- 592 14. B. Korber *et al.*, Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
593 Infectivity of the COVID-19 Virus. *Cell* **182**, 812-827 e819 (2020).
- 594 15. D. D. Zhou, W.; Supasa, P.; Liu, C.; Mentzer, A.J.; Ginn, H.M.; Zhao, Y.; Duyvesteyn, H.M.E.;
595 Tuekprakhon, A.; Nutalai, R.; Wang, B.; Paesen, G.C.; LopezCamacho, C.; Slon-Campos, J.;
596 Hallis, B.; Coombes, N.; Bewley, K.; Charlton, S.; Walter, T.S.; Skelly, D.; Lumley, S.F.; Dold, C.;
597 Levin, R.; Dong, T.; Pollard, A.J.; Knight, J.C.; Crook, D.; Lambe, T.; Clutterbuck, E.; Bibi, S.;
598 Flaxman, A.; Bittaye, M.; BelijRammerstorfer, S.; Gilbert, S.; James, W.; Carroll, M.W.;
599 Klenerman, P.; Barnes, E.; Dunachie, S.J.; Fry, E.E.; Mongkolsupaya, J.; Ren, J.; Stuart, D.I.;
600 Sreaton, G.R., Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine
601 induced sera *Cell*, (2021).
- 602 16. P. Wang *et al.*, Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. *Nature*,
603 (2021).
- 604 17. M. Hoffmann *et al.*, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by
605 a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278 (2020).

- 606 18. X. Tian *et al.*, Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-
607 specific human monoclonal antibody. *Emerg Microbes Infect* **9**, 382-385 (2020).
- 608 19. A. C. Walls *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
609 *Cell* **183**, 1735 (2020).
- 610 20. C. W. Tan *et al.*, A SARS-CoV-2 surrogate virus neutralization test based on antibody-
611 mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* **38**, 1073-1078
612 (2020).
- 613 21. C. Fenwick *et al.*, Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses
614 Impact the Estimates of Infections in Population-Based Seroprevalence Studies. *J Virol* **95**,
615 (2021).
- 616 22. D. Wrapp *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
617 *Science* **367**, 1260-1263 (2020).
- 618 23. C. M. Trombetta, E. Montomoli, Influenza immunology evaluation and correlates of
619 protection: a focus on vaccines. *Expert Rev Vaccines* **15**, 967-976 (2016).
- 620 24. P. Wang *et al.*, Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization.
621 *bioRxiv*, (2021).
- 622 25. A. Baum *et al.*, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational
623 escape seen with individual antibodies. *Science* **369**, 1014-1018 (2020).
- 624 26. N. Le Bert *et al.*, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and
625 uninfected controls. *Nature* **584**, 457-462 (2020).
- 626 27. S. A. Plotkin, Correlates of protection induced by vaccination. *Clin Vaccine Immunol* **17**, 1055-
627 1065 (2010).
- 628 28. Q. Li *et al.*, The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.
629 *Cell* **182**, 1284-1294 e1289 (2020).
- 630 29. Z. Liu *et al.*, Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and
631 serum antibody neutralization. *Cell Host Microbe* **29**, 477-488 e474 (2021).
- 632 30. R. C. H. Brown, D. Kelly, D. Wilkinson, J. Savulescu, The scientific and ethical feasibility of
633 immunity passports. *Lancet Infect Dis* **21**, e58-e63 (2021).
- 634 31. A. H. Mohammed, A. Blebil, J. Dujaili, B. A. Rasool-Hassan, The Risk and Impact of COVID-19
635 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant
636 Recipients. *AIDS Rev* **22**, 151-157 (2020).
- 637 32. P. Chen *et al.*, SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. *N*
638 *Engl J Med* **384**, 229-237 (2021).
- 639 33. D. M. Weinreich *et al.*, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with
640 Covid-19. *N Engl J Med* **384**, 238-251 (2021).

641